Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | VEGFA | P15692 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | UBE2N | P61088 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15069430 | 0.93 | BRD4 (0.48) | BRD4ELANEPRTN3L3MBTL1HTR6 | |
| SCHEMBL31395395 | 0.89 | BRD4 (0.41) | BRD4ELANEPRTN3L3MBTL1HTR6 | |
| SCHEMBL29455869 | 0.84 | BRD4 (0.38) | BRD4ELANEPRTN3HTR6VEGFA | |
| SCHEMBL29455995 | 0.83 | BRD4 (0.37) | BRD4ELANEPRTN3L3MBTL1HTR6 | |
| SCHEMBL24556539 | 0.82 | BRD4 (0.42) | BRD4CA1CA2KDM4E | |
| SCHEMBL29455808 | 0.81 | BRD4 (0.36) | BRD4ELANEPRTN3HTR6VEGFA | |
| SCHEMBL17749823 | 0.81 | BRD4 (0.36) | BRD4ELANEPRTN3HTR6VEGFA | |
| SCHEMBL17749821 | 0.81 | BRD4 (0.36) | BRD4ELANEPRTN3HTR6VEGFA | |
| SCHEMBL17749753 | 0.79 | BRD4 (0.37) | BRD4ELANEPRTN3HTR6VEGFA | |
| SCHEMBL19642608 | 0.79 | L3MBTL1 (0.39) | BRD4ELANEPRTN3L3MBTL1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162878-B2 | BRD4 inhibitor as well as a preparative method and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2024-12-10 | — | — | US | disclosed |
| EP-3831828-A1 | BRD4 INHIBITOR, PREPARATION METHOD AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-20210147419-A1 | BRD4 inhibitor as well as a preparative method and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147419-A1 | BRD4 inhibitor as well as a preparative method and use thereof | BICRA, BRD4, BRDT | BRD4 2/4885ELANE 4633/4885PRTN3 3199/4885 |
| US-12162878-B2 | BRD4 inhibitor as well as a preparative method and use thereof | BICRA, BRD4, BRDT | BRD4 2/4885ELANE 4633/4885PRTN3 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.